Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

119.24 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	35,313
Open	119.24
Bid (Size)	121.03 (100)
Ask (Size)	121.79 (400)
Prev. Close	119.24
Today's Range	119.24 - 119.24
52wk Range	73.31 - 122.66
Shares Outstanding	2,531,374,696
Dividend Yield	2.85%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven...

Via MarketMinute

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Via MarketMinute

Performance

YTD	+12.0%	+12.0%
1 Month	+10.1%	+10.1%
3 Month	+28.3%	+28.3%
6 Month	+44.1%	+44.1%
1 Year	+39.2%	+39.2%

More News

Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors ↗

February 03, 2026

Via Chartmill

Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market

February 12, 2026

Via Finterra

The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation

February 12, 2026

Via Finterra

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

February 12, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

February 11, 2026

From Merck & Co., Inc.

Via Business Wire

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

Via MarketMinute

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Via Finterra

5 Revealing Analyst Questions From Merck’s Q4 Earnings Call

February 10, 2026

Via StockStory

Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗

February 09, 2026

Via The Motley Fool

3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗

February 08, 2026

Via The Motley Fool

AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology

February 06, 2026

Via TokenRing AI

Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal

February 06, 2026

Via MarketMinute

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

Via MarketMinute

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

Via Finterra

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

Via Stocktwits

USDA Unveils $100 Million 'Grand Challenge' to Thwart Flesh-Eating Screwworm as Threat Reaches U.S. Border

February 05, 2026

Via MarketMinute

AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗

February 04, 2026

Via Chartmill

How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda ↗

February 04, 2026

Via Stocktwits

MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance

February 04, 2026

Via StockStory

Merck (MRK) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Via The Motley Fool

Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates

February 03, 2026

Via StockStory

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

February 03, 2026

From Merck & Co., Inc.

Via Business Wire

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

Via MarketMinute

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 119.24

When was Merck & Co last traded?

The last trade of Merck & Co was at 02/12/26 07:00 PM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 301.84B

How many shares of Merck & Co are outstanding?

Merck & Co has 302B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.